ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1198

Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis

Vanessa Kronzer1, Weixing Huang2, Paul Dellaripa3, Sicong Huang4, Vivi Feathers2, Bing Lu5, Christine Iannaccone6, Ritu Gill7, Hiroto Hatabu8, Mizuki Nishino8, Cynthia Crowson9, John Davis1, Michael Weinblatt4, Nancy Shadick10, Tracy J. Doyle11 and Jeffrey Sparks10, 1Mayo Clinic, Rochester, MN, 2Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Newton, MA, 6Division of General Internal Medicine; Brigham and Women’s Hospital, Topsfield, MA, 7Department of Radiology; Harvard Medical School, Beth Israel Deaconess Medical Center, Topsfield, MA, 8Department of Radiology; Brigham and Women’s Hospital, Boston, 9Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 10Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 11Brigham and Women's Hospital, West Roxbury, MA

Meeting: ACR Convergence 2020

Keywords: Epidemiology, interstitial lung disease, obesity, rheumatoid arthritis, Smoking

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite the known excess mortality of rheumatoid arthritis-associated interstitial lung disease (RA-ILD), its association with certain lifestyle factors such as obesity and future prediction have not yet been determined. We aimed to investigate the association between novel lifestyle factors on risk of incident RA-ILD, to define the threshold at which smoking increases risk of RA-ILD, and to calculate the degree to which known clinical risk factors predict RA-ILD.

Methods: This nested case-control study was performed within a prospective RA registry. All participants had RA confirmed by a rheumatologist using ACR/EULAR criteria. Three radiologists/pulmonologists determined incident RA-ILD status based on research review of clinically-obtained chest computed tomography (CT) scans. Controls had RA and no patient/physician report or billing codes for ILD. Index date was the first CT with RA-ILD or matched date. We matched each incident RA-ILD case to three controls on age, sex, RA duration, rheumatoid factor positivity, and time from exposure assessment to index date. Exposures were assessed at the earliest study visit prior to RA-ILD and included education, body mass index (BMI), smoking pack-years, anti-CCP positivity, race, hand bone erosions, rheumatoid nodules, CRP, DAS28-CRP, functional status (multi-dimensional HAQ [MDHAQ]), disease-modifying anti-rheumatic drug use, and glucocorticoid use. Conditional logistic regression models for each exposure determined odds ratios (OR) for RA-ILD, adjusting for matching factors, anti-CCP, race, education, BMI, and smoking pack-years. Area under the receiver operating characteristic curves (AUROC) were calculated based on lifestyle and clinical exposures.

Results: We identified 84 confirmed incident RA-ILD cases and 243 matched controls. RA-ILD cases had a mean age of 67 (standard deviation 10), and 77% were female. Mean time from exposure assessment to RA-ILD onset was 1.5 years. After adjustment, obesity, high-positive CRP (≥10 mg/L), and poor functional status (MDHAQ  ≥1) were each associated with increased risk of RA-ILD (Table 1). Smoking pack-year history greater than 30 was associated with a six-fold increased risk of RA-ILD compared to nonsmokers; less than 30 pack-years were not associated with RA-IOLD risk. Together, lifestyle and clinical risk factors for RA-ILD had an AUROC of 0.79 (95% CI 0.73-0.85) (Figure 1).

Conclusion: This study identified obesity, high-positive CRP, poor functional status, and a smoking threshold of 30 pack-years as novel predictors of RA-ILD. The overall ability to predict RA-ILD based on lifestyle and clinical factors was modest. Future studies should investigate whether smoking cessation and weight loss may delay or prevent RA-ILD. Additional factors such as biomarkers may improve prediction of RA-ILD among patients with RA.

Demographic factors: age, sex, race, education Lifestyle factors: BMI, smoking pack-years RA factors: RA duration, RF status, anti-CCP status, hand bone erosions, rheumatoid nodules, biologic DMARD use, methotrexate use, glucocorticoid use, disease activity (DAS28-CRP), functional status (MDHAQ).


Disclosure: V. Kronzer, None; W. Huang, None; P. Dellaripa, Genentech, 1, Bristol Myers Squibb, 1; S. Huang, None; V. Feathers, None; B. Lu, None; C. Iannaccone, None; R. Gill, None; H. Hatabu, None; M. Nishino, Merck, 1, Daiichi Sankyo, 1, 2, AstraZeneca, 1, 2, Canon Medical Systems grants, 1, Roche, 1; C. Crowson, Myriad Genetics, 1, Pfizer, 1; J. Davis, Pfizer, 2, AbbVie, 5, 8, Sanofi-Genzyme, 5, 8; M. Weinblatt, Crescendo Bioscience, 1, Bristol Myers Squibb, 1, Sanofi, 2, Lilly, 1, Amgen, 1, AbbVie, 5, Amgen, 2, 5, Arena, 5, Bristol Myers Squibb, 2, 5, Canfite, 1, 5, Corrona, 5, Crescendo, 2, 5, GlaxoSmithKline, 5, Gilead, 9, Horizon, 9, Johnson and Johnson, 9, Lilly, 2, 9, Pfizer, 9, Scipher, 1, 9, Set Point, 9, Roche, 9, Canfite, 1, Inmedix, 1, Lycera, 1, Vorso, 1, Scipher, 1; N. Shadick, Sanofi, 2, Crescendo Biosciences, 2, Lilly, 2, Bristol-Myers Squibb Company, 2, 5, Amgen, 2, Mallinckrodt, 2; T. Doyle, None; J. Sparks, Optum, 1, Janssen, 1, Inova, 1, Gilead, 1, Amgen, 1, Bristol-Myers Squibb, 1, 2.

To cite this abstract in AMA style:

Kronzer V, Huang W, Dellaripa P, Huang S, Feathers V, Lu B, Iannaccone C, Gill R, Hatabu H, Nishino M, Crowson C, Davis J, Weinblatt M, Shadick N, Doyle T, Sparks J. Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/lifestyle-and-clinical-risk-factors-for-incident-rheumatoid-arthritis-associated-interstitial-lung-disease-among-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lifestyle-and-clinical-risk-factors-for-incident-rheumatoid-arthritis-associated-interstitial-lung-disease-among-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology